Page last updated: 2024-12-06

bucindolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bucindolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA). It was initially developed for the treatment of hypertension and angina pectoris. Its mechanism of action involves blocking the binding of catecholamines, such as epinephrine and norepinephrine, to beta-adrenergic receptors in the heart and blood vessels. This blocking action leads to a decrease in heart rate, blood pressure, and myocardial contractility. Bucindolol also possesses vasodilatory properties, contributing to its antihypertensive effects. Research on bucindolol has been focused on its potential therapeutic benefits in cardiovascular diseases, particularly in patients with heart failure. Studies have explored its ability to improve left ventricular function, reduce mortality, and enhance exercise tolerance. However, despite promising preclinical and early clinical findings, bucindolol's development as a cardiovascular drug has been discontinued due to concerns regarding its safety profile, including potential side effects such as bradycardia and bronchospasm. Ongoing research continues to investigate the pharmacological properties of bucindolol and its potential applications in other areas, such as neuroprotection and cancer therapy.'

bucindolol: an indolyl-tert-butyl-phenoxypropanolamine benzonitrile derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51045
CHEMBL ID321582
SCHEMBL ID20138
MeSH IDM0082415

Synonyms (48)

Synonym
CHEMBL321582 ,
2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile
bucindolol [inn:ban]
mj 13105
bucindololum [inn-latin]
benzonitrile, 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-
bucindolol
OPREA1_648956
NCGC00167817-01
2-{2-hydroxy-3-[2-(1h-indol-3-yl)-1,1-dimethyl-ethylamino]-propoxy}-benzamide
bdbm50169808
2-{2-hydroxy-3-[2-(1h-indol-3-yl)-1,1-dimethyl-ethylamino]-propoxy}-benzonitrile
2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
cas-71119-11-4
tox21_112588
dtxsid3046744 ,
dtxcid1026744
BCP9000458
bucindololum
71119-11-4
unii-e9uo06k7ce
e9uo06k7ce ,
BCP0726000103
bucindolol [mi]
(+/-)-o-(2-hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile
bucindolol [who-dd]
bucindolol [inn]
o-(2-hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile
SCHEMBL20138
NCGC00167817-02
tox21_112588_1
FBMYKMYQHCBIGU-UHFFFAOYSA-N
2-(2-hydroxy-3-([2-(1h-indol-3-yl)-1,1-dimethylethyl]amino)propoxy)benzonitrile #
2-[2-hydroxy-3-[[2-(1h-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
AKOS024457224
2-[2-hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile
A903064
DB12752
2-(3-(1-(1h-indol-3-yl)-2-methylpropan-2-ylamino)-2-hydroxypropoxy)benzonitrile
2-(3-((1-(1h-indol-3-yl)-2-methylpropan-2-yl)amino)-2-hydroxypropoxy)benzonitrile
Q4982756
FT-0710537
SB16898
CS-0025305
HY-103214
dl-bucindolol
MS-25788
WCA11911

Research Excerpts

Overview

Bucindolol is a non-selective beta-blocker with mild vasodilator activity. It has been found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism. BucindolOL hydrochloride is a fourth-generation β-blockers in development for the treatment of CHF.

ExcerptReferenceRelevance
"Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrhythmic effects and increased efficacy for preventing heart failure events in patients homozygous for the major allele of the ADRB1 Arg389Gly polymorphism (ADRB1 Arg389Arg genotype)."( A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB, 2018
)
1.45
"Bucindolol is a beta-blocker whose unique pharmacologic properties provide greater benefit in HF patients with reduced ejection fraction (HFrEF) who have the beta"( Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
Abraham, WT; Aleong, R; Anand, IS; Ayala-Paredes, F; Bristow, MR; Carroll, IA; Connolly, SJ; Davis, G; Dufton, C; Emery, LL; Healey, JS; Ilkhanoff, L; Kao, DP; Khaykin, Y; Krueger, SK; Marshall, D; Merkely, B; Miloradović, V; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Wranicz, JK; Ziegler, PD, 2019
)
3.4
"Bucindolol is a novel beta-AR blocking agent that also lowers systemic norepinephrine and thus is also a sympatholytic agent."( An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
Abraham, WT; Anderson, JL; Bristow, MR; Carlquist, JF; Davis, GW; Krause-Steinrauf, H; Krishnan, V; Lavori, PW; Lazzeroni, LC; Liggett, SB; Lowes, BD; Murphy, GA; Port, JD; Robertson, AD; Thaneemit-Chen, S, 2010
)
1.29
"Bucindolol hydrochloride is a fourth-generation β-blocker in development for the treatment of CHF."( Bucindolol: new hopes from reviewing past data.
Fiuzat, M; O'Connor, CM, 2011
)
2.53
"Bucindolol is a β-blocker/sympatholytic agent whose efficacy is modulated by polymorphisms in the primary target (β(1) adrenergic receptor [AR] Arg389 Gly on cardiac myocytes) and a secondary target modifier (α(2C) AR Ins [wild-type (Wt)] 322-325 deletion [Del] on cardiac adrenergic neurons)."( Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.
Abraham, WT; Anand, IS; Bristow, MR; Carr, J; Carson, PE; Davis, G; Fiuzat, M; Gottlieb, SS; Lazzeroni, LC; Liggett, SB; Lindenfeld, J; Medway, A; Miller, AB; Murphy, GA; Nelson, P; O'Connor, CM; Plehn, JF; Port, JD; Robertson, AD; Silver, MA; Walsh, R; White, M, 2012
)
1.36
"Bucindolol is a newly developed, nonselective beta-adrenergic blocking agent with intrinsic sympathomimetic activity and direct vasodilator properties. "( Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
Fedder, IL; Ferguson, RK; Rocci, ML; Rotmensch, HH; Soyka, L; Swanson, BN; Vlasses, PH, 1984
)
3.15
"Bucindolol is a nonselective beta-blocking agent with mild vasodilatory properties. "( Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
Bristow, MR; French, WJ; Gilbert, EM; Kantrowitz, NE; Kelly, P; Leatherman, G; Marshall, G; O'Connell, JB; Orie, J; Smucker, ML, 1994
)
1.94
"Bucindolol hydrochloride is a phenoxypropanolamine with potent nonselective beta antagonist and mild vasodilatory properties. "( Effects of bucindolol in heart failure.
Eichhorn, EJ, 1993
)
2.12
"Bucindolol is a nonselective beta-adrenergic receptor antagonist that has additional vasodilating properties. "( Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors.
Cushing, DJ; Fink, GD; Silver, PJ; Watts, SW, 2000
)
2
"Bucindolol is a new beta blocker with marked vasodilatory properties and intrinsic sympathomimetic activity. "( Bucindolol, a beta blocker, decreased ventricular fibrillation and maintained mechanical function in a pig model of acute myocardial ischemia.
Muller, CA; Opie, LH; Peisach, M; Pineda, CA, 1992
)
3.17
"Bucindolol was found to be a high-affinity competitive beta-blocking agent as determined by bucindolol-[125I]iodocyanopindolol (ICYP) competition curves (KI = 3.7 +/- 1.3 x 10(-9) M, n = 10)."( Mechanism of action of bucindolol in human ventricular myocardium.
Bristow, MR; Hershberger, RE; Sundberg, L; Wynn, JR, 1990
)
1.31
"Bucindolol is a potent nonselective beta-blocking agent with vasodilatory properties. "( Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.
Anderson, JL; Bartholomew, M; Bristow, MR; Deitchman, D; Gilbert, EM; Larrabee, P; Mealey, PC; O'Connell, JB; Renlund, DG; Yanowitz, FG, 1990
)
1.92
"Bucindolol is a new beta blocker that has intrinsic nonadrenergically-mediated vasodilation and may be valuable in treatment of CHF."( Usefulness of bucindolol in congestive heart failure.
Craddock, G; Lystash, J; Pollock, SG; Smucker, ML; Tedesco, C, 1990
)
1.36
"Bucindolol is a new beta-adrenoceptor antagonist that lowers blood pressure partly via direct vasodilation. "( Bucindolol has serotonin and alpha-adrenoceptor blocking properties.
Marwood, JF; Stokes, GS, 1985
)
3.15
"Bucindolol is a nonselective beta blocker, possibly with other vasodilator properties."( Bucindolol in essential hypertension.
Curzio, J; Reid, JL; Vincent, J, 1985
)
2.43
"Bucindolol is a new nonselective beta-adrenergic blocking agent with direct vasodilator, partial agonist and alpha-adrenergic blocking properties. "( Hemodynamic properties of bucindolol, a beta-adrenoreceptor blocking drug with vasodilator activity.
Bett, N; Boyle, C; Dryburgh, L; Hawley, C, 1986
)
2.01
"Bucindolol is an investigational beta-adrenergic blocking agent with intrinsic sympathomimetic and vasodilatory activity in animals. "( Hemodynamic effects during rest and exercise of bucindolol in hypertensive men.
Clementi, RA; Conner, DP; Deitchman, D; Ferguson, RK; Oren, A; Vlasses, PH, 1987
)
1.97

Effects

Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. Bucindlol has shown promise in the treatment of patients with AF/HFrEF.

ExcerptReferenceRelevance
"Bucindolol has shown promise in the treatment of patients with AF/HFrEF."( Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.
Black-Maier, E; Piccini, JP; Steinberg, BA, 2015
)
2.58
"Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial."( Bucindolol displays intrinsic sympathomimetic activity in human myocardium.
Aiyar, N; Andreka, P; Bishopric, NH; Ohlstein, EH; Olson, LC; Turner, MS; Webster, KA; Wei, JQ, 2002
)
2.48

Actions

Bucindolol tended to increase forearm blood flow and decrease forearm vascular resistance (P less than .05 at 4 hr postdose) in comparison with placebo.

ExcerptReferenceRelevance
"The bucindolol group had an increase in systolic elastance, whereas the metoprolol group had a parallel left shift in this relation."( Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure.
Eichhorn, EJ; Hatfield, B; Heesch, CM; Marcoux, L, 1995
)
1.04
"Bucindolol tended to increase forearm blood flow and decrease forearm vascular resistance (P less than .05 at 4 hr postdose) in comparison with placebo."( Hemodynamic effects during rest and exercise of bucindolol in hypertensive men.
Clementi, RA; Conner, DP; Deitchman, D; Ferguson, RK; Oren, A; Vlasses, PH, 1987
)
1.25

Treatment

Bucindolol treatment did not alter oxidative stress, as determined by lipid peroxidation analysis and antioxidant enzyme activities and expression. Treatment also reduced RV pleomorphism, necrosis, fibrosis and infiltration of inflammatory cells.

ExcerptReferenceRelevance
"Bucindolol treatment did not alter oxidative stress, as determined by lipid peroxidation analysis and antioxidant enzyme activities and expression, endothelial nitric oxide synthase immunocontent and decreased nitrotyrosine levels."( Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension.
Belló-Klein, A; Bonetto, JHP; Colombo, R; de Lima-Seolin, BG; Fernandes, RO; Godoy, AEG; Hennemann, MM; Khaper, N; Litvin, IE; Sander da Rosa Araujo, A; Schenkel, PC; Teixeira, RB, 2018
)
2.64
"Bucindolol treatment also reduced RV pleomorphism, necrosis, fibrosis and infiltration of inflammatory cells."( Bucindolol improves right ventricle function in rats with pulmonary arterial hypertension through the reversal of autonomic imbalance.
Belló-Klein, A; Bonetto, JHP; Casali, KR; Colombo, R; Donatti, LM; Godoy, AEG; Lima-Seolin, BG; Litvin, IE; Rosa Araujo, ASD; Schenkel, PC; Teixeira, RB, 2017
)
2.62

Toxicity

ExcerptReferenceRelevance
"Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy."( Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Bucindolol caused a parallel shift to the right of the dose-response curves for both serotonin (5-HT) and phenylephrine (PE), indicating competitive antagonism. The mean terminal elimination half-life of bucindlol following acute oral dosing was 8.25 mg/kg.

ExcerptRelevanceReference
" Bucindolol caused a parallel shift to the right of the dose-response curves for both serotonin (5-HT) and phenylephrine (PE), indicating competitive antagonism."( Bucindolol has serotonin and alpha-adrenoceptor blocking properties.
Marwood, JF; Stokes, GS, 1985
)
2.62
"The effects of bucindolol a new nonselective beta blocker were studied after short-term dosing and for up to six months in eight patients with essential hypertension."( Bucindolol in essential hypertension.
Curzio, J; Reid, JL; Vincent, J, 1985
)
2.06
" This was most apparent in standing systolic and diastolic and post-exercise systolic blood pressures between 1 and 2 h after dosing and was dose-related."( A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
Jamieson, M; Petrie, JC; Robb, OJ; Verschueren, J; Webster, J, 1985
)
0.55
"25 mg/kg, bucindolol caused approximately 1000-fold and 100-fold shifts to the right in the dose-response curves for isoprenaline-induced chronotropic activity and hypotensive activity, respectively."( Studies in the rat on bucindolol, a new antihypertensive agent with beta-adrenoceptor blocking properties.
Oates, HF; Stoker, LM; Stokes, GS, 1981
)
0.98
") and shifted the dose-response curve for isoprenaline to higher agonist concentrations without altering HVC responses."( Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
Baker, JG; Fretwell, L; Gardiner, SM; Hill, SJ; Kemp, P; March, J, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency38.90180.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.71010.006038.004119,952.5996AID1159523
TDP1 proteinHomo sapiens (human)Potency22.42550.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.82800.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency31.76940.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.13170.000657.913322,387.1992AID1259378
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency12.58930.01237.983543.2770AID1346984
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.31380.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.77940.001530.607315,848.9004AID1224841; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency28.18380.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.52050.000229.305416,493.5996AID743075
cytochrome P450 2D6Homo sapiens (human)Potency0.15490.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency15.67930.001019.414170.9645AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency29.28740.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency23.71010.001628.015177.1139AID1224843
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency2.81840.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.27180.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency21.13000.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency11.88560.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency8.91250.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)27.20000.21005.553710.0000AID386625
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.05000.00002.015110.0000AID241889
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)27.20002.03005.53139.9000AID386625
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID194405Vasodilator activity in ganglion blocked rats. Values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 3 mg/kg intravenously1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID193106The compound was tested for beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 2 mg/kg1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID170444Antihypertensive activity in spontaneously hypertensive rats after peroral administration1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID241889Inhibitory activity against recombinant human Cytochrome P450 2D6 (CYP2D6) after incubated for 45 minutes2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID171589Intrinsic sympathomimetic action in reserpinized rats1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (20.71)18.7374
1990's25 (17.86)18.2507
2000's44 (31.43)29.6817
2010's33 (23.57)24.3611
2020's9 (6.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.81 (24.57)
Research Supply Index5.19 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials38 (26.95%)5.53%
Reviews24 (17.02%)6.00%
Case Studies1 (0.71%)4.05%
Observational0 (0.00%)0.25%
Other78 (55.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure [NCT00832442]18,240 participants (Anticipated)Observational2008-08-31Enrolling by invitation
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure [NCT01970501]Phase 2267 participants (Actual)Interventional2014-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01970501 (4) [back to overview]Number of Patients With Adequate Ventricular Rate Control During the 24-week Follow-up Period
NCT01970501 (4) [back to overview]Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24].
NCT01970501 (4) [back to overview]Time to First Event of Symptomatic or Asymptomatic AF/AFL or ACM During the 24-week Follow-up Period After Establishment of Stable SR on Study Drug [End of Treatment Week 24]
NCT01970501 (4) [back to overview]Total Number of Hospitalization Days Per Patient (All-cause) During the Total Study Period (24 Weeks)

Number of Patients With Adequate Ventricular Rate Control During the 24-week Follow-up Period

Number of patients with adequate ventricular rate control following the start of medication during the 24-week Follow-up Period (NCT01970501)
Timeframe: end of treatment week 24

InterventionParticipants (Count of Participants)
Bucindolol Hydrochloride84
Metoprolol Succinate116

[back to top]

Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24].

Time-to-event is calculated as the date of the event minus the date of initiation of efficacy follow-up, with 1 added in order to include both the start date and end date of the interval. Cox's proportional hazards model will be used to calculate estimated hazard ratios and 95% confidence intervals. The calculations will be performed with the SAS PHREG procedure, with the stratification variables specified in the STRATA statement and the treatment group comparator and any covariates being examined specified in the MODEL statement. For the primary endpoint, the appropriateness of assuming proportional hazards will be explored by the graphing of log (-log(survival function)) over follow-up for each treatment group. (NCT01970501)
Timeframe: end of treatment week 24

Interventiondays (Mean)
Bucindolol Hydrochloride35.9
Metoprolol Succinate33.2

[back to top]

Time to First Event of Symptomatic or Asymptomatic AF/AFL or ACM During the 24-week Follow-up Period After Establishment of Stable SR on Study Drug [End of Treatment Week 24]

Number of days on study medication before participant experienced symptomatic or asymptomatic atrial fibrillation, atrial flutter, or all-cause mortality during the 24 week follow up period. (NCT01970501)
Timeframe: end of treatment week 24

Interventiondays (Mean)
Bucindolol Hydrochloride37.86
Metoprolol Succinate31.06

[back to top]

Total Number of Hospitalization Days Per Patient (All-cause) During the Total Study Period (24 Weeks)

Total number of hospitalization days per patient (all-cause) following the start of study medication during the Total Study Period (24 weeks). Hospitalization was defined by a hospital admission (note that same day admit and discharge equates to 0 days duration), ER visits were not counted as events. (NCT01970501)
Timeframe: 24 weeks

Interventiondays (Median)
Bucindolol Hydrochloride2
Metoprolol Succinate2

[back to top]